Skip to main content
SpringerLink
Log in

Adjuvant monoclonal antibody 17-1A therapy improves survival in colorectal cancer

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Martindale. The Extra Pharmacopoeia, 31st ed. London: Pharmaceutical Press, 1996: 528

    Google Scholar 

  2. Slevin ML. Adjuvant treatment for colorectal cancer: no more room for nihilism. Br Med J 1996 Feb 17; 312: 392–3

    Article  CAS  Google Scholar 

  3. NIH Consensus Panel. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444–50

    Article  Google Scholar 

  4. Holz E, Gruber R, Riethmüller G. Monoclonal antibodies in cancer chemotherapy: new perspectives after the colorectal carcinoma trial. Clin Immunother 1996 Mar; 5(3): 214–22

    Article  Google Scholar 

  5. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 1994 May 14; 343: 1177–83

    Article  PubMed  Google Scholar 

  6. Moertel CG, Fleming TR, MacDonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321–6

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adjuvant monoclonal antibody 17-1A therapy improves survival in colorectal cancer. Drugs Ther. Perspect 8, 5–7 (1996). https://doi.org/10.2165/00042310-199608110-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199608110-00002

Search

Navigation